<?xml version="1.0" encoding="UTF-8"?>
<p>Havrylyuk etÂ al. screened novel 4-thiazolidinone benzothiazole derivatives against ovarian, renal, prostate, leukaemia, melanoma, lung, colon, CNS and breast cancer cell lines. The thioxothiazolidine acetamide benzothiazole 
 <bold>52</bold> (
 <xref ref-type="fig" rid="F0032">Figure 32</xref>) showed the most promising anti-cancer activity. The SAR studies pinpointed that the introduction of 4-chloro-phenoxy-
 <italic>N</italic>-(4-methoxyphenyl)-acetamide substitutions on position 5 of the 4-thiazolidinones ring enhanced the anti-cancer potential
 <xref rid="CIT0053" ref-type="bibr">
  <sup>53</sup>
 </xref>.
</p>
